Hamakawa Masamitsu, Ishida Tadashi
Department of Respiratory Medicine Kurashiki Central Hospital Okayama Japan.
Respirol Case Rep. 2024 Aug 15;12(8):e70009. doi: 10.1002/rcr2.70009. eCollection 2024 Aug.
It is an absolute necessity to achieve complete control of comorbidities to obtain optimal asthma control. Importantly, type 2 asthma and ECRS share the same inflammatory pathophysiology and are common co-morbidities. If the initial biologic is insufficiently effective, it is worth considering an alternative biologic.
要实现哮喘的最佳控制，完全控制合并症是绝对必要的。重要的是，2型哮喘和鼻息肉病有相同的炎症病理生理学，且是常见的合并症。如果初始生物制剂疗效不足，值得考虑换用另一种生物制剂。
